Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer

Simple item page
dc.contributor.authorOstwal, Vikasen_US
dc.contributor.authorBose, Subhadeepen_US
dc.contributor.authorSirohi, Bhawnaen_US
dc.contributor.authorPoladia, Bhaveshen_US
dc.contributor.authorSahu, Arvinden_US
dc.contributor.authorBhargava, Prabhaten_US
dc.contributor.authorDoshi, Vipulen_US
dc.contributor.authorDusane, Rohiten_US
dc.contributor.authorNashikkar, Chaitalien_US
dc.contributor.authorShrikhande, Shailesh Ven_US
dc.contributor.authorRamaswamy, Ananten_US
dc.date.accessioned2020-01-02T06:27:59Z
dc.date.available2020-01-02T06:27:59Z
dc.date.issued2018-01
dc.description.abstractIntroduction: Docetaxel/oxaliplatin/capecitabine (TEX) is a commonly used combination chemotherapeutic regimen in advanced gastric cancer (AGC). Application strategies in routine clinical practice are reported in this study. Materials and Methods: Patients diagnosed with AGC, receiving biweekly TEX (docetaxel - 60 mg/m (2)-D1; oxaliplatin - 85 mg/m (2)-D1, and capecitabine 500–625 mg/m (2) orally twice daily for 14 days) between July 2012 and May 2016 were retrospectively analyzed for tolerance, prognostic factors, event-free survival (EFS), and overall survival (OS). The proportion of patients continuing and terminating chemotherapy at various time-points was enumerated. Results: Overall, 208 patients were started on TEX. Median EFS was 6.34 months (95% confidence interval [CI] 5.80–6.87), and median OS was 15.31 (95% CI 12.65–17.96). Post 8 cycles of TEX, further 30 patients (14.4%) were continued on chemotherapy (docetaxel, capecitabine, or TEX) whereas 47 patients (22.6%) were on observation only, and there was a statistically significant difference in the median OS of these two groups (22.55 months vs. 14.89 months; P = 0.028). Raised serum alkaline phosphatase (SAP) levels (>100 U/L) predicted inferior survival (P = 0.006). Conclusion: TEX chemotherapy is a feasible, efficacious triplet regimen that can be used in clinical practice. SAP levels >100 U/L is a poor prognostic factor, as observed in this study. An initial “induction” such as combination chemotherapy regimen followed by monotherapy as continuation requires further evaluationen_US
dc.identifier.affiliationsDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of Medical Oncology, Barts Cancer Institute, Queen Mary University of London, London, UKen_US
dc.identifier.affiliationsH M Patel Center for Medical Care and Education, Karamsad, Gujarat, Indiaen_US
dc.identifier.affiliationsStatistician (Clinical Research Secretariat), Tata Memorial Hospital, Mumbai, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationOstwal Vikas, Bose Subhadeep, Sirohi Bhawna, Poladia Bhavesh, Sahu Arvind, Bhargava Prabhat, Doshi Vipul, Dusane Rohit, Nashikkar Chaitali, Shrikhande Shailesh V, Ramaswamy Anant. Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. Indian Journal of Cancer. 2018 Jan; 55(1): 88-93en_US
dc.identifier.issn0019-509X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/190325
dc.languageenen_US
dc.publisherIndian Cancer Societyen_US
dc.relation.issuenumber1en_US
dc.relation.volume55en_US
dc.source.urihttps://dx.doi.org//10.4103/ijc.IJC_353_17en_US
dc.titleDocetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijoc2018v55n1p88.pdf
Size:
604.28 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Cancer